Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Published Online
on February 2, 2004

Circulation. 2004
Published online before print February 2, 2004, doi: 10.1161/01.CIR.0000112595.65972.8A
A more recent version of this article appeared on February 24, 2004
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
109/7/932    most recent
01.CIR.0000112595.65972.8Av1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yun, J. J.
Right arrow Articles by Ardehali, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yun, J. J.
Right arrow Articles by Ardehali, A.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Substance via MeSH
Medline Plus Health Information
*Heart Transplantation
Related Collections
Right arrow Transplantation
Right arrow CV surgery: transplantation, ventricular assistance, cardiomyopathy
Right arrow Chronic ischemic heart disease
Right arrow Mechanism of atherosclerosis/growth factors

Submitted on October 3, 2003
Revised on October 17, 2003
Accepted on October 21, 2003

Combined Blockade of the Chemokine Receptors CCR1 and CCR5 Attenuates Chronic Rejection

James J. Yun MD, PhD, David Whiting MD, Michael P. Fischbein MD, PhD, Anamika Banerji BS, Yoshihito Irie MD, Daniel Stein BS, Michael C. Fishbein MD, Amanda E.I. Proudfoot PhD, Hillel Laks MD, Judith A. Berliner PhD, and Abbas Ardehali MD*

From the Department of Surgery, Division of Cardiothoracic Surgery (J.J.Y., M.P.F., A.B., Y.I., D.S., H.L., A.A.) and Department of Pathology and Laboratory Medicine (J.J.Y., M.C.F., J.A.B.), University of California at Los Angeles, Los Angeles, Calif; Greater Los Angeles Veterans Administration Healthcare System (J.J.Y., A.A.), Los Angeles, Calif; and Serono Pharmaceutical Research Institute (A.E.I.P.), Geneva, Switzerland.

* To whom correspondence should be addressed. E-mail: aardehali{at}mednet.ucla.edu.

Background--Chemokine-chemokine receptor interaction and the subsequent recruitment of T-lymphocytes to the graft are early events in the development of chronic rejection of transplanted hearts or cardiac allograft vasculopathy (CAV). In this study, we sought to determine whether blockade of chemokine receptors CCR1 and CCR5 with Met-RANTES affects the development of CAV in a murine model.

Methods and Results--B6.CH-2bm12 strain donor hearts were transplanted heterotopically into wild-type C57BL/6 mice (myosin heavy chain II mismatch). Recipients were treated daily with either Met-RANTES or vehicle starting on postoperative day 4 and were euthanized on postoperative days 24 and 56. We found that Met-RANTES significantly reduced intimal thickening in this model of chronic rejection and that Met-RANTES markedly decreased the infiltration of CD4 and CD8 T lymphocytes and MOMA-2+ monocytes/macrophages into transplanted hearts. Met-RANTES also suppressed the ex vivo and in vitro proliferative responses of recipient splenocytes to donor antigens. Finally, Met-RANTES treatment was associated with a marked reduction in RANTES/CCL5 and monocyte chemoattractant protein-1 gene transcript levels in the donor hearts.

Conclusions--Antagonism of the chemokine receptors CCR1 and CCR5 with Met-RANTES attenuates CAV development in vivo by reducing mononuclear cell recruitment to the transplanted heart, proliferative responses to donor antigens, and intragraft RANTES/CCL5 and monocyte chemoattractant protein-1 gene transcript levels. These findings suggest that chemokine receptors CCR1 and CCR5 play significant roles in the development of chronic rejection and may serve as potential therapeutic targets.


Key words: transplantation • lymphocytes • rejection • chemokine




This article has been cited by other articles:


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
A. Schober
Chemokines in Vascular Dysfunction and Remodeling
Arterioscler Thromb Vasc Biol, November 1, 2008; 28(11): 1950 - 1959.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
J. A Belperio and A. Ardehali
Chemokines and Transplant Vasculopathy
Circ. Res., August 29, 2008; 103(5): 454 - 466.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
G. T. Schnickel, S. Bastani, G. R. Hsieh, A. Shefizadeh, R. Bhatia, M. C. Fishbein, J. Belperio, and A. Ardehali
Combined CXCR3/CCR5 Blockade Attenuates Acute and Chronic Rejection
J. Immunol., April 1, 2008; 180(7): 4714 - 4721.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. W. Choi, G. C. Hildebrandt, K. M. Olkiewicz, D. A. Hanauer, M. N. Chaudhary, I. A. Silva, C. E. Rogers, D. T. Deurloo, J. M. Fisher, C. Liu, et al.
CCR1/CCL5 (RANTES) receptor-ligand interactions modulate allogeneic T-cell responses and graft-versus-host disease following stem-cell transplantation
Blood, November 1, 2007; 110(9): 3447 - 3455.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
V. Mayer, K. L. Hudkins, F. Heller, H. Schmid, M. Kretzler, U. Brandt, H.-J. Anders, H. Regele, P. J. Nelson, C. E. Alpers, et al.
Expression of the chemokine receptor CCR1 in human renal allografts
Nephrol. Dial. Transplant., June 1, 2007; 22(6): 1720 - 1729.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. van Loosdregt, M. F.M. van Oosterhout, A. H. Bruggink, D. F. van Wichen, J. van Kuik, E. de Koning, C. C. Baan, N. de Jonge, F. H.J. Gmelig-Meyling, and R. A. de Weger
The Chemokine and Chemokine Receptor Profile of Infiltrating Cells in the Wall of Arteries With Cardiac Allograft Vasculopathy Is Indicative of a Memory T-Helper 1 Response
Circulation, October 10, 2006; 114(15): 1599 - 1607.
[Abstract] [Full Text] [PDF]


Home page
Protein Eng Des SelHome page
M. Notohamiprodjo, R. Djafarzadeh, A. Mojaat, I. von Luttichau, H.-J. Grone, and P. J. Nelson
Generation of GPI-linked CCL5 based chemokine receptor antagonists for the suppression of acute vascular damage during allograft transplantation
Protein Eng. Des. Sel., January 1, 2006; 19(1): 27 - 35.
[Abstract] [Full Text] [PDF]


Home page
Int ImmunolHome page
Z. F. Yang, D. W. Ho, C. K. Lau, C. T. Lam, C. T. Lum, R. T. P. Poon, and S. T. Fan
Allograft inflammatory factor-1 (AIF-1) is crucial for the survival and pro-inflammatory activity of macrophages
Int. Immunol., November 1, 2005; 17(11): 1391 - 1397.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
G. C. Hildebrandt, K. M. Olkiewicz, S. Choi, L. A. Corrion, S. G. Clouthier, C. Liu, J. S. Serody, and K. R. Cooke
Donor T-cell production of RANTES significantly contributes to the development of idiopathic pneumonia syndrome after allogeneic stem cell transplantation
Blood, March 15, 2005; 105(6): 2249 - 2257.
[Abstract] [Full Text] [PDF]